Neutrophil-to-lymphocyte ratio (NLR) was shown to be prognostic in several solid malignancies. There are limited data about predictive/prognostic value of NLR during targeted therapy of patients with advanced gastrointestinal stromal tumors (GIST). The aim of the study was to asses a clinical value of this ratio in patients with advanced GIST.
Between 2001 and 2016, 385 patients with metastatic/unresectable GIST treated initially with imatinib were included to the analysis. In all patients the NLR was assessed at the baseline, after 3 months of treatment and upon disease progression (or last observation). The cut off for NLR was set at 2.7. Kaplan-Meier survival probability estimation with in log-rank test, and Cox's proportional hazards model were used for analysis.
Median Progression-Free Survival (PFS) on imatinib treatment was 44.8 months, 5-year rate 43%; median Disease Specific Survival (DSS) – 87.2 months, 10-year rate 36.3%. NLR >2.7 at baseline was significantly associated with poorer OS and DSS: median DSS was 89.3 months (95%CI 80.2-115) for NLR ratio ≤2.7 vs. 59.4 months (95%CI 48.6-82) for NLR >2.7 (p
Our results demonstrate the usefulness of NLR as a prognostic and predictive marker as well as marker for treatment monitoring in patients with advanced GIST treated with imatinib.
Clinical trial identification
Legal entity responsible for the study
Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland
P. Rutkowski: I have received honoraria for lectures from Novartis, Roche, Pfizer, BMS, MSD and served as a member of Advisory Board for Novartis, Merck, Amgen, Blueprint, Roche, BMs and MSD.
All other authors have declared no conflicts of interest.